Stock ACET ADICET BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Adicet Bio, Inc.

Equities

ACET

US0070021086

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
1.49 USD -2.61% Intraday chart for Adicet Bio, Inc. -6.88% -21.16%
May. 14 Adicet Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 22 Adicet Bio, Inc. Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the ASGCT 27th Annual Meeting CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Adicet Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates
BU
Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress
BU
Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference
BU
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
BU
Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy 27th Annual Meeting
AQ
Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
BU
Adicet Bio, Inc. Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the ASGCT 27th Annual Meeting
CI
Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference
BU
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
BU
North American Morning Briefing : Markets Steady -2-
DJ
Adicet Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Adicet Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
BU
Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
BU
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
BU
JonesTrading Upgrades Adicet Bio to Buy From Hold, Price Target is $6
MT
Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
BU
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
BU
Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ACET Stock
  4. News Adicet Bio, Inc.